People are becoming cautious of viral vector vaccines: Biotech analyst
Jason Kolbert, director of research at Dawson James Securities, joins BNN Bloomberg for his outlook on U.S. health officials pausing the Johnson & Johnson vaccine in response to six blood clot reports.
